2nd Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,144,727
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2022 $1,144,727 Replaced
2nd Quarter - Amendment Jul 27, 2022 $1,144,727 Replaced
2nd Quarter - Amendment Jul 27, 2022 $1,144,727 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 4128 (117th), S. 3593 (117th), S. 2209 (117th), H.R. 8188 (117th), H.R. 8152 (117th), S. 3799 (117th), S. 4348 (117th), S. 4449 (117th), H.R. 7667 (117th), H.R. 7007 (117th)

Medicare/Medicaid MMM

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE

Bills named: H.R. 8188 (117th), S. 4449 (117th)

Budget/Appropriations BUD

Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; SENATE; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 8152 (117th), H.R. 7007 (117th), S. 4348 (117th), H.R. 7667 (117th), H.R. 4128 (117th), S. 3799 (117th), S. 2209 (117th)

Health Issues HCR

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 4348 (117th), S. 4449 (117th), H.R. 8188 (117th), S. 3593 (117th), H.R. 7667 (117th), H.R. 8152 (117th), S. 3799 (117th), H.R. 7007 (117th), S. 2209 (117th), H.R. 4128 (117th)

Disaster Planning/Emergencies DIS

Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 4128 (117th), S. 4348 (117th), H.R. 7007 (117th), S. 2209 (117th), S. 3799 (117th), H.R. 8152 (117th), H.R. 7667 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.